Prognostic significance of tumor-related proteases as a function of the estrogen receptor status

Cancer Biology and Therapy

Volumn 11, Issue 2, 2011, Pages 277-283

  Mazouni, Chafika ^a,b,e   Romain, Sylvie ^b   Bonnier, Pascal ^c   Ouafik, L'houcine ^b,d   Martin, Pierre Marie ^b  

^a IGR ^*  (France)

^b Laboratoire de Transfert Biologique Oncologique   (France)

^c Clinique Beauregard   (France)

^d University of the Mediterranean Aix Marseille II   (France)

^e INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

Breast cancer; Cathepsin D; Estrogen receptor; Overall survival; PAI 1; Proteases; uPA

Indexed keywords

CATHEPSIN D; ESTROGEN RECEPTOR; PLASMINOGEN ACTIVATOR INHIBITOR; UROKINASE;

ADULT; ARTICLE; BREAST CANCER; CANCER PATIENT; CANCER SURVIVAL; CONTROLLED STUDY; ENZYME BLOOD LEVEL; HIGH RISK PATIENT; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PRIMARY TUMOR; PROGNOSIS; PROSPECTIVE STUDY; TUMOR VOLUME;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CATHEPSIN D; FEMALE; HUMANS; LONGITUDINAL STUDIES; MIDDLE AGED; NEOPLASMS; PEPTIDE HYDROLASES; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROGNOSIS; RECEPTORS, ESTROGEN; SURVIVAL ANALYSIS; UROKINASE-TYPE PLASMINOGEN ACTIVATOR;

EID: 78751530866     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.11.2.13964     Document Type: Article

References (40)

1. Edwards DP, Chamness GC, McGuire WL. Estrogen and progesterone receptor proteins in breast cancer. Biochim Biophys Acta 1979; 560:457-86.
2. Fisher B, Redmond C, Fisher ER, Caplan R. Relative worth of estrogen or progesterone receptor and pathologic characteristics of differentiation as indicators of prognosis in node negative breast cancer patients: findings from National Surgical Adjuvant Breast and Bowel Project Protocol B-06. J Clin Oncol 1988; 6:1076-87.
3. Harris L, Fritsche H, Mennel R, Norton L, Ravdin P, Taube S, et al. American Society of Clinical Oncology. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 2007; 25:5287-312.
4. Kos J, Lah TT. Cysteine proteinases and their endogenous inhibitors: target proteins for prognosis, diagnosis and therapy in cancer (review). Oncol Rep 1998; 5:1349-61.
5. Rao JS. Molecular mechanisms of glioma invasiveness: the role of proteases. Nat Rev Cancer 2003; 3:489-501.
6. Schmitt M, Harbeck N, Thomssen C, Wilhelm O, Magdolen V, Reuning U, et al. Clinical impact of the plasminogen activation system in tumor invasion and metastasis: prognostic relevance and target for therapy. Thromb Haemost 1997; 78:285-96.
7. López-Otín C, Matrisian LM. Emerging roles of proteases in tumour suppression. Nature Reviews Cancer 2007; 7:800-8.
8. Liotta LA, Goldfarb RH, Brundage R, Siegal GP, Terranova V, Garbisa S. Effect of plasminogen activator (urokinase), plasmin and thrombin on glycoprotein and collagenous components of basement membrane. Cancer Res 1981; 41:4629-36.
9. Danø K, Andreasen PA, Grøndahl-Hansen J, Kristensen P, Nielsen LS, Skriver L. Plasminogen activators, tissue degradation and cancer. Adv Cancer Res 1985; 44:139-266.
10. Lyons RM, Moses HL. Transforming growth factors and the regulation of cell proliferation. Eur J Biochem 1990; 187:467-73.
11. Wakefield LM, Yang YA, Dukhanina O. Transforming growth factorbeta and breast cancer: Lessons learned from genetically altered mouse models. Breast Cancer Res 2000; 2:100-6.
12. Lyons RM, Keski-Oja J, Moses HL. Proteolytic activation of latent transforming growth factor-beta from fibroblast-conditioned medium. J Cell Biol 1988; 106:1659-65.
13. Look M, van Putten W, Duffy M, Harbeck N, Christensen IJ, Thomssen C, et al. Pooled analysis of prognostic impact of uPA and PAI-1 in breast cancer patients. Thromb Haemost 2003; 90:538-48.
14. Harbeck N, Kates RE, Look MP, Meijer-Van Gelder ME, Klijn JG, Krüger A, et al. Enhanced benefit from adjuvant chemotherapy in breast cancer patients classified high-risk according to urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (n = 3,424). Cancer Res 2002; 62:4617-22.
15. Annecke K, Schmitt M, Euler U, Zerm M, Paepke D, Paepke S, et al. uPA and PAI-1 in breast cancer: review of their Clinical utility and current validation in the prospective NNBC-3 trial. Adv Clin Chem 2008; 45:31-45.
16. Grøndahl-Hansen J, Peters HA, van Putten WL, Look MP, Pappot H, Rønne E, et al. Prognostic significance of the receptor for urokinase plasminogen activator in breast cancer. Clin Cancer Res 1995; 1:1079-87.
17. Duffy MJ, Reilly D, McDermott E, O'Higgins N, Fennelly JJ, Andreasen PA. Urokinase plasminogen activator as a prognostic marker in different subgroups of patients with breast cancer. Cancer 1994; 74:2276-80.
18. Foucré D, Bouchet C, Hacène K, Pourreau-Schneider N, Gentile A, Martin PM, et al. Relationship between cathepsin D, urokinase and plasminogen activator inhibitors in malignant vs. benign breast tumours. Br J Cancer 1991; 64:926-32.
19. Gion M, Mione R, Dittadi R, Romanelli M, Pappagallo L, Capitanio G, et al. Relationship between cathepsin D and other pathological and biological parameters in 1,752 patients with primary breast cancer. Eur J Cancer 1995; 31:671-7.
20. Thorpe SM, Christensen IJ, Rasmussen BB, Rose C. Short recurrence-free survival associated with high oestrogen receptor levels in the natural history of postmenopausal, primary breast cancer. Eur J Cancer 1993; 29:971-7.
21. American Joint Committee on Cancer: AJCC Cancer Staging Manual. New York NY, Springer 2002; 6:221-40.
22. Romain S, Spyratos F, Lainé-Bidron C, Bouchet C, Guirou O, Martin PM, et al. Comparative study of four extraction procedures for urokinase type plasminogen activator and plasminogen activator inhibitor-1 in breast cancer tissues. Eur J Clin Chem Clin Biochem 1995; 33:603-8.
23. Romain S, Bendahl PO, Guirou O, Malmström P, Martin PM, Fernö M. DNA-synthesizing enzymes in breast cancer (thymidine kinase, thymidylate synthase and thymidylate kinase): association with flow cytometric S-phase fraction and relative prognostic importance in node-negative premenopausal patients. Int J Cancer 2001; 95:56-61.
24. Harbeck N, Alt U, Berger U, Krüger A, Thomssen C, Jänicke F, et al. Prognostic impact of proteolytic factors (urokinase-type plasminogen activator, plasminogen activator inhibitor 1 and cathepsins B, D and L) in primary breast cancer reflects effects of adjuvant systemic therapy. Clin Cancer Res 2001; 7:2757-64.
25. Garbett EA, Reed MW, Brown NJ. Proteolysis in human breast and colorectal cancer. Br J Cancer 1999; 81:287-93.
26. Jahkola T, Toivonen T, von Smitten K, Virtanen I, Wasenius VM, Blomqvist C. Cathepsin-D, urokinase plasminogen activator and type-1 plasminogen activator inhibitor in early breast cancer: an immunohistochemical study of prognostic value and relations to tenascin-C and other factors. Br J Cancer 1999; 80:167-74.
27. Marsigliante S, Biscozzo L, Greco S, Leo G, Storelli C. Relation of cathepsin D level to the estrogen receptor in human breast cancer. Int J Clin Lab Res1992; 22:52-7.
28. Marsigliante S, Biscozzo L, Correale M, Paradiso A, Leo G, Abbate I, et al. Immunoradiometric detection of pS2 and total cathepsin D in primary breast cancer biopsies: their correlation with steroid receptors. Br J Cancer 1994; 69:550-4.
29. Kute TE, Grøndahl-Hansen J, Shao SM, Long R, Russell G, Brünner N. Low cathepsin D and low plasminogen activator type 1 inhibitor in tumor cytosols defines a group of node negative breast cancer patients with low risk of recurrence. Breast Cancer Res Treat 1998; 47:9-16.
30. Westley B, Rochefort H. A secreted glycoprotein induced by estrogen in human breast cancer cell lines. Cell 1980; 20:353-62.
31. Garcia M, Lacombe MJ, Duplay H, Cavailles V, Derocq D, Delarue JC, et al. Immunohistochemical distribution of the 52 kDa protein in mammary tumors: a marker associated with cell proliferation rather than with hormone responsiveness. J Steroid Biochem 1987; 27:439-45.
32. Broët P, Spyratos F, Romain S, Quillien V, Daver A, Ricolleau G, et al. Prognostic value of uPA and p53 accumulation measured byquantitative biochemical assays in 1,245 primary breast cancer patients: a multicentre study. Br J Cancer 1999; 80:536-45.
33. Andreasen PA, Georg B, Lund LR, Riccio A, Stacey SN. Plasminogen activator inhibitors: hormonally regulated serpins. Mol Cell Endocrinol 1990; 68:1-19.
34. Tong D, Czerwenka K, Sedlak J, Schneeberger C, Schiebel I, Concin N, et al. Association of in vitro invasiveness and gene expression of estrogen receptor, progesterone receptor, pS2 and plasminogen activator inhibitor-1 in human breast cancer cell lines. Breast Cancer Res Treat 1999; 56:91-7.
35. Foekens JA, Peters HA, Look MP, Portengen H, Schmitt M, Kramer MD, et al. The urokinase system of plasminogen activation and prognosis in 2,780 breast cancer patients. Cancer Res 2000; 60:636-43.
36. Foekens JA, Schmitt M, van Putten WL, Peters HA, Kramer MD, Jänicke F, et al. Plasminogen activator inhibitor-1 and prognosis in primary breast cancer. J Clin Oncol 1994; 12:1648-58.
37. Foekens JA, Look MP, Bolt-de Vries J, Meijer-van Gelder ME, van Putten WL, Klijn JG. Cathepsin-D in primary breast cancer: prognostic evaluation involving 2,810 patients. Br J Cancer 1999; 79:300-7.
38. Henry JA, McCarthy AL, Angus B, Westley BR, May FE, Nicholson S, et al. Prognostic significance of the estrogen-regulated protein, cathepsin D, in breast cancer. An immunohistochemical study. Cancer 1990; 65:265-71.
39. Rochefort H, Chalbos D, Cunat S, Lucas A, Platet N, Garcia M. Estrogen regulated proteases and antiproteases in ovarian and breast cancer cells. J Steroid Biochem Mol Biol 2001; 76:119-24.
40. Rochefort H, Glondu M, Sahla ME, Platet N, Garcia M. How to target estrogen receptor-negative breast cancer? Endocr Relat Cancer 2003; 10:261-6.